Apyx Medical Corporation, an energy technology company, designs, develops, manufactures, and sells electrosurgical equipment and medical devices in the United States and internationally. The company operates through two segments: Surgical Aesthetics and Original Equipment Manufacturing (OEM). It offers helium plasma generator for the delivery of RF energy and helium plasma to cut, coagulate, and ablate soft tissue during open and minimally invasive surgical procedures; and a portfolio of single-use handpieces and accessories for open and laparoscopic procedures. The company’s helium plasma technology products are marketed and sold under the Renuvion name in the cosmetic surgery market and under the J-Plasma name in the hospital surgical market. It also develops and manufactures OEM generators and related accessories. The company was formerly known as Bovie Medical Corporation and changed its name to Apyx Medical Corporation in January 2019. Apyx Medical Corporation was incorporated in 1982 and is based in Clearwater, Florida.
Apyx Medical Corporation Reports Second Quarter 2026 Financial Results
Apyx Medical reported Q2 2026 total revenue of $13.9 million, up 22% year-over-year, driven primarily by a 28% increase in the Surgical Aesthetics segment to $12.4 million.
The company narrowed its net loss to $3.2 million, or $0.07 per share, compared to a loss of $3.8 million in the prior year period, while cash and cash equivalents stood at $27.6 million.
Operational highlights include a limited commercial launch of the AYON power liposuction handpiece following FDA clearance, and management reaffirmed full-year 2026 revenue guidance of $59.0 million to $60.0 million.